Biodesix Inc (BDSX)vsNovartis AG ADR (NVS)
BDSX
Biodesix Inc
$15.32
-0.97%
HEALTHCARE · Cap: $113.91M
NVS
Novartis AG ADR
$145.39
-2.00%
HEALTHCARE · Cap: $275.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 63831% more annual revenue ($56.58B vs $88.50M). NVS leads profitability with a 23.9% profit margin vs -39.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
BDSX
Avoid30
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.7%
Fair Value
$19.42
Current Price
$15.32
$4.10 discount
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$145.39
$35.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 40.8% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -383.1% — below average capital efficiency
Negative free cash flow — burning cash
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 40.8% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : BDSX
The primary concerns for BDSX are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BDSX profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
BDSX is growing revenue faster at 40.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 23.9% margins. BDSX offers better value entry with a 46.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?